- Trials with a EudraCT protocol (151)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
151 result(s) found for: Discovery.
Displaying page 1 of 8.
EudraCT Number: 2011-001783-21 | Sponsor Protocol Number: 3288 | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Childrens's Research Institute | |||||||||||||
Full Title: Optimizing Pain Treatment in Pre-Term Neonates | |||||||||||||
Medical condition: Critically Ill Premature Neonates between 23 and 32 weeks of gestation who are receiving morphine as part of their routine medical management of pain or other medically indicated condition for whic... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000586-19 | Sponsor Protocol Number: 307971 | Start Date*: 2005-07-25 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) | ||
Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-000563-41 | Sponsor Protocol Number: IMIMFTCL/GH/4 | Start Date*: 2014-08-08 |
Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar) | ||
Full Title: Recombinant hGH Biomarkers Discovery | ||
Medical condition: Healthy volunteers. There is not intended indication. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021951-26 | Sponsor Protocol Number: UoL000621/R&D3963 | Start Date*: 2011-04-15 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or m... | |||||||||||||
Medical condition: Locally advanced or metastatic pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002969-19 | Sponsor Protocol Number: REN001-101 | Start Date*: 2019-01-29 | |||||||||||
Sponsor Name:Reneo Pharma Ltd. | |||||||||||||
Full Title: An open-label study to evaluate the safety and tolerability of 12 weeks treatment with oral REN001 in patients with primary mitochondrial myopathy (PMM), with an optional extension of treatment | |||||||||||||
Medical condition: Primary mitochondrial myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006639-24 | Sponsor Protocol Number: 2020/ABM/01/00080 | Start Date*: 2022-10-19 |
Sponsor Name:The Cardinal Stefan Wyszyński Institute of Cardiology | ||
Full Title: Multicenter Polish Study of the Use of Bromocriptine in Perinatal Cardiomyopathy. New BioMarkers in the Early Diagnosis of Peripartum CardioMyopathy. PolBrom-PPCM | ||
Medical condition: PeriPartum Cardiomiopathy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003812-19 | Sponsor Protocol Number: ZPL389/102 | Start Date*: 2015-12-07 | |||||||||||
Sponsor Name:Ziarco Pharma Ltd | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL ZPL-3893787-18 (30 MG) ADMINISTERED FOR 12 WEEKS IN ADULT ... | |||||||||||||
Medical condition: PLAQUE PSORIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002855-40 | Sponsor Protocol Number: REN001-201 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:Reneo Pharma Ltd. | |||||||||||||
Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 24 WEEKS TREATMENT WITH REN001 IN PATIENTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM) | |||||||||||||
Medical condition: Primary Mitochondrial Myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) DK (Completed) HU (Completed) BE (Completed) IT (Completed) ES (Ongoing) NL (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023193-39 | Sponsor Protocol Number: COT-HSCSP-2009-02 | Start Date*: 2011-05-10 |
Sponsor Name:Fundación Institut de Recerca de l'Hospital de la Sta Creu i Sant Pau | ||
Full Title: "Ensayo clínico aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para la valoración de la eficacia del zoledronato endovenoso para disminución de la resorción periprotésica en... | ||
Medical condition: La disminución de la masa ósea periprotésica, que determina las propiedades mecánicas del hueso alrededor del implante. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016068-35 | Sponsor Protocol Number: DRI11073 | Start Date*: 2010-02-19 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Completed) LT (Completed) AT (Completed) CZ (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000936-23 | Sponsor Protocol Number: C20-15 | Start Date*: 2020-03-09 |
Sponsor Name:INSERM | ||
Full Title: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults | ||
Medical condition: COVID-19 - Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 72 hours prior to randomization. - Illness of any durat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) BE (Completed) AT (Completed) PT (Completed) SK (Completed) CZ (Completed) NO (Prematurely Ended) IE (Prematurely Ended) HU (Completed) ES (Ongoing) GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004653-14 | Sponsor Protocol Number: UoL000097 | Start Date*: 2015-04-17 |
Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | ||
Full Title: A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma. (ACELARATE) | ||
Medical condition: Metastatic pancreatic carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000976-27 | Sponsor Protocol Number: ML2017-IO1 | Start Date*: 2017-07-26 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment | ||
Medical condition: advanced urothelial cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003471-34 | Sponsor Protocol Number: REN001-202 | Start Date*: 2022-04-19 | |||||||||||
Sponsor Name:Reneo Pharma Ltd. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF REN001 IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM) | |||||||||||||
Medical condition: Primary Mitochondrial Myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) HU (Prematurely Ended) NL (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000577-11 | Sponsor Protocol Number: VAP00027 | Start Date*: 2022-07-29 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc | |||||||||||||
Full Title: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Completed) DK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000576-19 | Sponsor Protocol Number: VAP00026 | Start Date*: 2022-07-29 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc | |||||||||||||
Full Title: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared with Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age. | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007482-21 | Sponsor Protocol Number: Version 2.2 | Start Date*: 2009-11-09 | ||||||||||||||||
Sponsor Name:Salford Royal NHS Foundation Trust | ||||||||||||||||||
Full Title: Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + A... | ||||||||||||||||||
Medical condition: Fabry disease with proteinuria. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005845-30 | Sponsor Protocol Number: Td506-LT | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: One-, Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents (11-64 ... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001963-35 | Sponsor Protocol Number: MET50 | Start Date*: 2016-05-06 |
Sponsor Name:Sanofi Pasteur Inc. | ||
Full Title: A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents | ||
Medical condition: Healthy volunteers (active immunization against invasive meningococcal disease (IMD) caused by Meningococcal serogroups A, C, Y or W | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-009372-13 | Sponsor Protocol Number: 2009-01b | Start Date*: 2009-11-03 |
Sponsor Name:Institut de Cancérologie de la Loire | ||
Full Title: A phase II, multi-center, open-label, repeat-dose study of Lenalidomide (Revlimid ®) plus low-dose Dexamethasone in patients with refractory B-cell lineage acute lymphoblastic leukemia or in relaps... | ||
Medical condition: Treatment for B-cell Acute lymphoblastic leukemia in relapse. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
